文献速递膀胱癌与上尿路尿路上皮癌

尿液FGFR3和TERT基因突变分析提升Cxbladder检测性能并改善患者风险分层

Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.
PubMed 文献 · J Urol · 2022-12-30

两项多中心前瞻性研究纳入804例血尿患者(肉眼血尿484例、镜下血尿320例),在现有5种mRNA标志物和临床风险因素基础上增加FGFR3和TERT基因6个单核苷酸多态性DNA分析,开发增强型Cxbladder检测。增强型Cxbladder-Detect对尿路上皮癌检测敏感性97%、特异性90%、阴性预测值99.7%,特异性显著优于第一代Cxbladder检测(P < .001)。

要点

  • 增强型Cxbladder-Detect对尿路上皮癌敏感性97%、特异性90%、阴性预测值99.7%。
  • 83%患者为增强型Cxbladder-Detect阴性,即无需进一步检查。
  • 增强型Cxbladder检测特异性显著优于第一代Cxbladder检测(P < .001)。

核心结论

  • 在种族多样的血尿患者中,本研究显示增强型Cxbladder检测具有分析有效性。

研究设计与样本

  • 两项多中心前瞻性研究:美国≥18岁肉眼血尿患者和新加坡>21岁肉眼血尿或镜下血尿患者,所有患者提供中段尿样本并接受膀胱镜检查。
  • 样本采用增强型Cxbladder-Triage、增强型Cxbladder-Detect及两者组合进行回顾性分析。

主要发现

  • 汇总队列N=804(肉眼血尿n=484,镜下血尿n=320),增强型Cxbladder-Detect检测尿路上皮癌敏感性97%(95%CI 89%-100%)、特异性90%(95%CI 88%-92%)、阴性预测值99.7%(95%CI 99%-100%)。
  • 83%患者为增强型Cxbladder-Detect阴性,即无需进一步检查。
  • 133例增强型Cxbladder-Detect阳性患者中59例确认肿瘤,其中19例为低级别非浸润性乳头状癌或低恶性潜能乳头状尿路上皮肿瘤。
  • 共40个肿瘤为高级别Ta、T1-T4、Tis,包括伴发原位癌。
  • 74例膀胱镜检查正常患者中41例单核苷酸多态性分析阳性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cxbladder tests are urinary biomarker tests for detection of urothelial carcinoma. We developed enhanced Cxbladder tests that incorporate DNA analysis of 6 single nucleotide polymorphisms for the FGFR3 and TERT genes, in addition to the current 5 mRNA biomarkers and clinical risk factors. MATERIALS AND METHODS: Two multicenter, prospective studies were undertaken in: (1) U.S. patients with gross hematuria aged ≥18 years and (2) Singaporean patients with gross hematuria or microhematuria aged >21 years. All patients provided a midstream urine sample and underwent cystoscopy. Samples were retrospectively analyzed using enhanced Cxbladder-Triage (risk stratifies patients), enhanced Cxbladder-Detect (risk stratifies patients and detects positive patients), and the combination enhanced Cxbladder-Triage × Cxbladder-Detect. RESULTS: In the pooled cohort (N=804; gross hematuria: n=484, microhematuria: n=320), enhanced Cxbladder-Detect had a sensitivity of 97% (95% CI 89%-100%), specificity of 90% (95% CI 88%-92%), and negative predictive value of 99.7% (95% CI 99%-100%) for detection of urothelial carcinoma. Overall, 83% of patients were enhanced Cxbladder-Detect-negative (ie, needed no further work-up). Of 133 enhanced Cxbladder-Detect-positive patients, 59 had a confirmed tumor, of which 19 were low-grade noninvasive papillary carcinoma or papillary urothelial neoplasm of low malignant potential. In total, 40 tumors were high-grade Ta, T1-T4, Tis, including concomitant carcinoma in situ. Of the 74 patients with normal cystoscopy, 41 were positive by single nucleotide polymorphism analysis. Enhanced Cxbladder-Triage and enhanced Cxbladder-Detect had significantly better specificity than the first-generation Cxbladder tests (P < .001). CONCLUSIONS: This study in ethnically diverse patients with hematuria showed the analytical validity of the enhanced Cxbladder tests.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lotan Y, Raman JD, Konety B, et al. Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. J Urol. 2022. PMID: 36583640. doi:10.1097/JU.0000000000003126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。